Literature DB >> 2945043

[Tetanus vaccination--tolerance and prevention of side effects].

G Korger, U Quast, G Dechert.   

Abstract

Data collected over a 15-year period concerning the side effects directly reported following administration of Tetanol were evaluated and it was found that the tetanus vaccination exhibited an extremely high degree of tolerance, with only 27 cases of side effects for 1 million doses. In over 80% of those cases with side effects the intolerance took the form of a painful reddening and/or swelling at the site of injection. This reaction to the vaccination, though not uncommon, was thus greater than is to be expected. General reactions, particularly malaise and an increase in body temperature, accounted for 10% of the cases reported; 3% involved skin reactions beyond the injection site. Symptoms involving the cardiac, circulatory, respiratory, locomotor, or nervous system occurred in fewer than 3 cases per 1 million doses, i.e., in fewer than 5% of the reported cases. It proved highly improbable that an allergic-anaphylactic or anaphylactoid reaction was involved and the complete picture of anaphylactic shock was never observed. Young and middle-aged adults with several tetanus pre-vaccinations accounted for the majority of side effects reported and in most cases hyperimmunization was suspected as a cause. As they were mainly restricted to the site of application and in 75% of cases occurred within 2-48 h, they can be interpreted as type III reactions (Arthus type). Furthermore it can be assumed that other causes of the reactions will have included unintentional intravascular and subcutaneous administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945043     DOI: 10.1007/bf01732184

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  27 in total

1.  REACTIONS TO TETANUS TOXOID: A REPORT OF FIVE CASES.

Authors:  C H SCHNEIDER
Journal:  Med J Aust       Date:  1964-08-22       Impact factor: 7.738

2.  DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose.

Authors:  L J Baraff; C L Cody; J D Cherry
Journal:  Pediatrics       Date:  1984-01       Impact factor: 7.124

3.  Neurologic complications of tetanus toxoid.

Authors:  G M Fenichel
Journal:  Arch Neurol       Date:  1983-06

4.  Life-threatening anaphylactic reaction to tetanus toxoid.

Authors:  G P Zaloga; B Chernow
Journal:  Ann Allergy       Date:  1982-08

5.  [Neurologic disorders following tetanus vaccination. A case report].

Authors:  K Dieckhöfer; R Scholl; R Wolf
Journal:  Med Welt       Date:  1978-11-03

6.  Unusual neurological complications following tetanus toxoid administration.

Authors:  G K Schlenska
Journal:  J Neurol       Date:  1977-07-20       Impact factor: 4.849

7.  Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults.

Authors:  M G Myers; C W Beckman; R A Vosdingh; W A Hankins
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

8.  Reactions to tetanus toxoid.

Authors:  F J Kittler; P Smith; B F Hefley; A G Cazort
Journal:  South Med J       Date:  1966-02       Impact factor: 0.954

9.  Peripheral neuropathy after multiple tetanus toxoid injections.

Authors:  L Reinstein; J M Pargament; J S Goodman
Journal:  Arch Phys Med Rehabil       Date:  1982-07       Impact factor: 3.966

10.  [Immune status after tetanus vaccination. Possibilities and indications for a quantitative rapid determination of tetanus antibodies in human serum].

Authors:  A Holzner
Journal:  Fortschr Med       Date:  1978-04-06
View more
  2 in total

Review 1.  Vaccination of adults against travel-related infectious diseases, and new developments in vaccines.

Authors:  P C Döller
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

2.  Acute midbrain syndrome as an adverse reaction to tetanus immunization.

Authors:  G Schwarz; G Lanzer; W F List
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.